Literature DB >> 17287624

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.

Guy Young1, Karyn E Yonekawa, Peggy A Nakagawa, Rachelle C Blain, Amy E Lovejoy, Diane J Nugent.   

Abstract

New anticoagulants, including the direct thrombin inhibitors (DTIs) and fondaparinux, are increasingly replacing unfractionated heparin and enoxaparin. We examined the effects of argatroban (n = 60), bivalirudin (n = 44), heparin (n = 14), enoxaparin (n = 22), and fondaparinux (n = 24) on clot formation utilizing thromboelastography. Blood samples containing anticoagulants at clinically relevant concentrations were prepared ex vivo and analyzed using kaolin or tissue factor activation. Thromboelastography parameters of clot initiation (R), clot propagation (K and angle), clot rigidity (maximum amplitude) and clot elasticity (G) were compared between anticoagulants. Thromboelastography was also performed on blood from eight patients receiving anticoagulants. Each anticoagulant exerted significant concentration-dependent effects on R, K and angle. Only heparin, enoxaparin, and fondaparinux significantly affected maximum amplitude and G. Significant differences existed for all parameters between heparin and each anticoagulant and between fondaparinux and each DTI (P < 0.001), and for angle, maximum amplitude, and G between enoxaparin and each DTI (P < 0.008). Thromboelastography responses in ex-vivo samples and patient samples were comparable. In conclusion, whereas argatroban, bivalirudin, heparin, enoxaparin and fondaparinux each delay clot formation, the DTIs do not alter clot rigidity or elasticity. The reduced bleeding reported with DTIs versus heparin may relate to the fact that clots form with normal rigidity and elasticity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287624     DOI: 10.1097/MBC.0b013e3280116c4c

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

2.  Successful Management of Thrombosis of the Proximal Aorta after Implantation with a Biventricular Assist Device.

Authors:  Mark J Russo; Claudia Gidea; Ravi Karanam; David A Baran; Craig R Saunders; Mark J Zucker; Margarita T Camacho
Journal:  J Extra Corpor Technol       Date:  2014-12

Review 3.  Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.

Authors:  Marcie J Hursting; Joseph Soffer
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass.

Authors:  Shvetank Agarwal; Beth Ullom; Yasser Al-Baghdadi; Michael Okumura
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-01

5.  Optical sensing of anticoagulation status: Towards point-of-care coagulation testing.

Authors:  Diane M Tshikudi; Markandey M Tripathi; Zeinab Hajjarian; Elizabeth M Van Cott; Seemantini K Nadkarni
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.